Stock AnalizStaar Surgical Co. STAA
Ophthalmic Goods · data as of November 13, 2026
Staar Surgical Co. (STAA) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to October 2, 2026 it had revenue of $328M and net income of $530000, a net margin of 0.2%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 2639.0, a price to free cash flow of 74.2, 5-year revenue growth of 8% a year, a 5-year average ROIC of -0%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 88% below the current price.
Score: 1.2 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $328M | $239M | $314M | $322M | $239M | $230M | $163M | $150M | $124M | $91M | $82M |
| Net income | $530000 | -$80M | -$20M | $21M | $40M | $28M | $6M | $14M | $5M | -$2M | -$12M |
| Free cash flow | $18M | -$40M | -$8M | -$4M | $18M | $30M | $13M | $16M | $11M | $2M | -$2M |
| EPS (diluted) | $0.01 | $-1.62 | $-0.41 | $0.43 | $0.80 | $0.56 | $0.12 | $0.30 | $0.11 | $-0.05 | $-0.30 |
| Net margin | 0.2% | -33.6% | -6.4% | 6.6% | 16.6% | 11.9% | 3.6% | 9.3% | 4.0% | -2.4% | -14.7% |
| ROIC | — | -23.4% | -2.3% | 4.2% | 10.4% | 10.0% | 2.3% | 5.6% | 3.6% | -7.1% | -29.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $28.56, 8% above the current price; targets range from $19.00 to $37.00; the consensus rating is “Buy”; expected EPS is $0.93 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Staar Surgical’s P/E ratio?
About 2639.0, based on the last twelve months of diluted earnings per share (forward P/E about 25.4).
Is Staar Surgical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 88% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Staar Surgical pay a dividend?
Not currently.
Is Staar Surgical a good stock to buy?
We do not give buy or sell advice. Staar Surgical scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.